MedTrace Logo

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

NCT03590808 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2019-09-19

No results posted yet for this study

Summary

The purpose of this study is to elucidate efficacy and safety of influenza vaccine in cancer patients receiving immune checkpoint inhibitor.

Conditions

Interventions

BIOLOGICAL

Influenza vaccination

Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM

Sponsors & Collaborators

  • Green Cross Corporation

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Wan Beom Park, M.D., PhD. · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2018-12-21
Completion
2019-05-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03590808 on ClinicalTrials.gov